MOTIVATION: In the field of drug discovery, accurately and effectively predicting the binding affinity between proteins and ligands is crucial for drug screening and optimization. However, current research primarily utilizes representations based on sequence or structure to predict protein-ligand binding affinity, with relatively less study on protein surface information, which is crucial for protein-ligand interactions. Moreover, when dealing with multimodal information of proteins, traditional approaches typically concatenate features from different modalities in a straightforward manner without considering the heterogeneity among them, which results in an inability to effectively exploit the complementary between modalities. RESULTS: We introduce a novel multimodal feature extraction (MFE) framework that, for the first time, incorporates information from protein surfaces, 3D structures, and sequences, and uses cross-attention mechanism for feature alignment between different modalities. Experimental results show that our method achieves state-of-the-art performance in predicting protein-ligand binding affinity. Furthermore, we conduct ablation studies that demonstrate the effectiveness and necessity of protein surface information and multimodal feature alignment within the framework. AVAILABILITY AND IMPLEMENTATION: The source code and data are available at https://github.com/Sultans0fSwing/MFE.

MOTIVATION: Molecular representation learning plays an indispensable role in crucial tasks such as property prediction and drug design. Despite the notable achievements of molecular pre-training models, current methods often fail to capture both the structural and feature semantics of molecular graphs. Moreover, while graph contrastive learning has unveiled new prospects, existing augmentation techniques often struggle to retain their core semantics. To overcome these limitations, we propose a gradient-compensated encoder parameter perturbation approach, ensuring efficient and stable feature augmentation. By merging enhancement strategies grounded in attribute masking and parameter perturbation, we introduce MoleMCL, a new MOLEcular pre-training model based on multi-level contrastive learning. RESULTS: Experimental results demonstrate that MoleMCL adeptly dissects the structure and feature semantics of molecular graphs, surpassing current state-of-the-art models in molecular prediction tasks, paving a novel avenue for molecular modeling. AVAILABILITY AND IMPLEMENTATION: The code and data underlying this work are available in GitHub at https://github.com/BioSequenceAnalysis/MoleMCL.

Potential miRNA-disease associations (MDA) play an important role in the discovery of complex human disease etiology. Therefore, MDA prediction is an attractive research topic in the field of biomedical machine learning. Recently, several models have been proposed for this task, but their performance limited by over-reliance on relevant network information with noisy graph structure connections. However, the application of self-supervised graph structure learning to MDA tasks remains unexplored. Our study is the first to use multi-view self-supervised contrastive learning (MSGCL) for MDA prediction. Specifically, we generated a learner view without association labels of miRNAs and diseases as input, and utilized the known association network to generate an anchor view that provides guiding signals for the learner view. The graph structure was optimized by designing a contrastive loss to maximize the consistency between the anchor and learner views. Our model is similar to a pre-trained model that continuously optimizes upstream tasks for high-quality association graph topology, thereby enhancing the latent representation of association predictions. The experimental results show that our proposed method outperforms state-of-the-art methods by 2.79$\%$ and 3.20$\%$ in area under the receiver operating characteristic curve (AUC) and area under the precision/recall curve (AUPR), respectively.

Accumulated studies discovered that various microbes in human bodies were closely related to complex human diseases and could provide new insight into drug development. Multiple computational methods were constructed to predict microbes that were potentially associated with diseases. However, most previous methods were based on single characteristics of microbes or diseases, that lacked important biological information related to microorganisms or diseases. Therefore, we constructed a knowledge graph centered on microorganisms and diseases from several existed databases to provide knowledgeable information for microbes and diseases. Then, we adopted a graph neural network method to learn representations of microbes and diseases from the constructed knowledge graph. After that, we introduced the Gaussian kernel similarity features of microbes and diseases to generate final representations of microbes and diseases. At last, we proposed a score function on final representations of microbes and diseases to predict scores of microbe-disease associations. Comprehensive experiments on the Human Microbe-Disease Association Database (HMDAD) dataset had demonstrated that our approach outperformed baseline methods. Furthermore, we implemented case studies on two important diseases (asthma and inflammatory bowel disease), the result demonstrated that our proposed model was effective in revealing the relationship between diseases and microbes. The source code of our model and the data were available on https://github.com/ChangzhiJiang/KGNMDA_master.

Identifying new lead molecules to treat cancer requires more than a decade of dedicated effort. Before selected drug candidates are used in the clinic, their anti-cancer activity is generally validated by in vitro cellular experiments. Therefore, accurate prediction of cancer drug response is a critical and challenging task for anti-cancer drugs design and precision medicine. With the development of pharmacogenomics, the combination of efficient drug feature extraction methods and omics data has made it possible to use computational models to assist in drug response prediction. In this study, we propose DeepTTA, a novel end-to-end deep learning model that utilizes transformer for drug representation learning and a multilayer neural network for transcriptomic data prediction of the anti-cancer drug responses. Specifically, DeepTTA uses transcriptomic gene expression data and chemical substructures of drugs for drug response prediction. Compared to existing methods, DeepTTA achieved higher performance in terms of root mean square error, Pearson correlation coefficient and Spearman's rank correlation coefficient on multiple test sets. Moreover, we discovered that anti-cancer drugs bortezomib and dactinomycin provide a potential therapeutic option with multiple clinical indications. With its excellent performance, DeepTTA is expected to be an effective method in cancer drug design.

Researches have found that tumor immunotherapy can only work for some patients, and the intestinal microbiota is one of the important factors affecting the responses of patients with cancer to immune checkpoint blockade therapy. It is highly desirable to develop computational methods that can predict whether a patient with cancer will have positive effects on cancer immunotherapy by analyzing intestinal microorganisms of the patient. In this study, a multi-task model is introduced to predict the efficacy of cancer immunotherapy on a patient who suffered from non-small cell lung cancer or renal cell carcinoma. The results demonstrate the multi-task model outperforms several single-task methods. Therefore, we believe the multi-task idea can be used to predict the efficacy of cancer immunotherapy based on the gut microbe, which would be important to cancer patients.